{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:16:45Z","timestamp":1785187005399,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00277-022-04880-1","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T15:03:13Z","timestamp":1655823793000},"page":"1655-1666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"101","author":[{"given":"Meghavi","family":"Kathpalia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinki","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Bajpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Bhurani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-3026","authenticated-orcid":false,"given":"Nidhi","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"4880_CR1","unstructured":"Puckett Y; OC (2020) Acute lymphocytic leukemia - StatPearls - NCBI Bookshelf"},{"key":"4880_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2016-03-643544.The","volume":"2","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A (2016) The updated WHO classification of hematological malignancies: the 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia. Blood J 2:58\u201371. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.The","journal-title":"Blood J"},{"key":"4880_CR3","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(74)90466-8","volume":"303","author":"L Freedman","year":"1974","unstructured":"Freedman L, Dent NA, Hunt C et al (1974) Incidence of childhood leuk\u00e6mia. Lancet 303:1059. https:\/\/doi.org\/10.1016\/S0140-6736(74)90466-8","journal-title":"Lancet"},{"key":"4880_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","volume":"2016","author":"EA Raetz","year":"2016","unstructured":"Raetz EA, Teachey DT (2016) T-cell acute lymphoblastic. leukemia Hematol (United States) 2016:580\u2013588. https:\/\/doi.org\/10.1182\/asheducation-2016.1.580","journal-title":"leukemia Hematol (United States)"},{"key":"4880_CR5","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ajh.25957","volume":"95","author":"A Candoni","year":"2020","unstructured":"Candoni A, Lazzarotto D, Ferrara F et al (2020) Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study. Am J Hematol 95:1466\u20131472. https:\/\/doi.org\/10.1002\/ajh.25957","journal-title":"Am J Hematol"},{"key":"4880_CR6","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/pbc.25470.Safe","volume":"62","author":"SS Winter","year":"2016","unstructured":"Winter SS, Dunsmore KP, Devidas M et al (2016) HHS Public Access 62:1176\u20131183. https:\/\/doi.org\/10.1002\/pbc.25470.Safe","journal-title":"HHS Public Access"},{"key":"4880_CR7","doi-asserted-by":"publisher","unstructured":"Ronson A, Tvito A, Rowe JM (2016) Treatment of relapsed\/refractory acute lymphoblastic leukemia in adults. Curr Oncol Rep 18:.https:\/\/doi.org\/10.1007\/s11912-016-0519-8","DOI":"10.1007\/s11912-016-0519-8"},{"key":"4880_CR8","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","volume":"376","author":"C Parker","year":"2010","unstructured":"Parker C, Waters R, Leighton C et al (2010) Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 376:2009\u20132017. https:\/\/doi.org\/10.1016\/S0140-6736(10)62002-8","journal-title":"Lancet"},{"key":"4880_CR9","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","volume":"28","author":"G Tallen","year":"2010","unstructured":"Tallen G, Ratei R, Mann G et al (2010) Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 28:2339\u20132347. https:\/\/doi.org\/10.1200\/JCO.2009.25.1983","journal-title":"J Clin Oncol"},{"key":"4880_CR10","first-page":"219","volume":"2","author":"KM Reilly","year":"2009","unstructured":"Reilly KM, Kisor DF (2009) Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther 2:219\u2013228","journal-title":"Onco Targets Ther"},{"key":"4880_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.26909","volume":"65","author":"T Oskarsson","year":"2018","unstructured":"Oskarsson T, S\u00f6derh\u00e4ll S, Arvidson J et al (2018) Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 65:1\u201310. https:\/\/doi.org\/10.1002\/pbc.26909","journal-title":"Pediatr Blood Cancer"},{"key":"4880_CR12","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1177\/1078155218817816","volume":"25","author":"O Mustafa","year":"2019","unstructured":"Mustafa O, Abdalla K, AlAzmi AA et al (2019) FLAG\/FLAG-IDA regimen for children with relapsed\/refractory acute leukemia in the era of targeted novel therapies. J Oncol Pharm Pract 25:1831\u20131838. https:\/\/doi.org\/10.1177\/1078155218817816","journal-title":"J Oncol Pharm Pract"},{"key":"4880_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/03007995.2017.1384373","volume":"34","author":"A Crotta","year":"2018","unstructured":"Crotta A, Zhang J, Keir C (2018) Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory b-cell acute lymphoblastic leukemia. Curr Med Res Opin 34:435\u2013440. https:\/\/doi.org\/10.1080\/03007995.2017.1384373","journal-title":"Curr Med Res Opin"},{"key":"4880_CR14","first-page":"70","volume":"2","author":"T Bauters","year":"2011","unstructured":"Bauters T, Robays H, Benoit Y, De MB (2011) Treatment of refractory T-lympho- blastic leukaemia and lymphoma with nelarabine. Belgian J Hematol 2:70\u201374","journal-title":"Belgian J Hematol"},{"key":"4880_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/bjh.14877","volume":"179","author":"M Kuhlen","year":"2017","unstructured":"Kuhlen M, Bleckmann K, M\u00f6ricke A et al (2017) Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy. Br J Haematol 179:272\u2013283. https:\/\/doi.org\/10.1111\/bjh.14877","journal-title":"Br J Haematol"},{"key":"4880_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.currproblcancer.2016.11.005","volume":"41","author":"C Lalayanni","year":"2017","unstructured":"Lalayanni C, Baldoumi E, Papayiannopoulos S et al (2017) Nelarabine-associated reversible Guillain-Barr\u00e9\u2013like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma. Curr Probl Cancer 41:138\u2013143. https:\/\/doi.org\/10.1016\/j.currproblcancer.2016.11.005","journal-title":"Curr Probl Cancer"},{"key":"4880_CR17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","volume":"86","author":"DA Thomas","year":"1999","unstructured":"Thomas DA, Kantarjian H, Smith TL et al (1999) Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 86:1216\u20131230. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19991001)86:7%3c1216::AID-CNCR17%3e3.0.CO;2-O","journal-title":"Cancer"},{"key":"4880_CR18","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","volume":"38","author":"KP Dunsmore","year":"2020","unstructured":"Dunsmore KP, Winter SS, Devidas M et al (2020) Children\u2019s oncology group AALL0434: A phase III randomized clinical trial testing nelarabine in newly diagnosed t-cell acute lymphoblastic leukemia. J Clin Oncol 38:3282\u20133293. https:\/\/doi.org\/10.1200\/JCO.20.00256","journal-title":"J Clin Oncol"},{"key":"4880_CR19","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","volume":"118","author":"N G\u00f6kbuget","year":"2011","unstructured":"G\u00f6kbuget N, Basara N, Baurmann H et al (2011) High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation. Blood 118:3504\u20133511. https:\/\/doi.org\/10.1182\/blood-2011-01-329441","journal-title":"Blood"},{"key":"4880_CR20","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","volume":"109","author":"DJ DeAngelo","year":"2007","unstructured":"DeAngelo DJ, Yu D, Johnson JL et al (2007) Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and Leukemia Group B study 19801. Blood 109:5136\u20135142. https:\/\/doi.org\/10.1182\/blood-2006-11-056754","journal-title":"Blood"},{"key":"4880_CR21","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-06-0606","volume":"12","author":"MH Cohen","year":"2006","unstructured":"Cohen MH, Johnson JR, Massie T et al (2006) Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia\/lymphoma. Clin Cancer Res 12:5329\u20135335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0606","journal-title":"Clin Cancer Res"},{"key":"4880_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1365-2141.2010.08236.x","volume":"150","author":"LA Commander","year":"2010","unstructured":"Commander LA, Seif AE, Insogna IG, Rheingold SR (2010) Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed\/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma: research paper. Br J Haematol 150:345\u2013351. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08236.x","journal-title":"Br J Haematol"},{"key":"4880_CR23","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/leu.2013.312","volume":"28","author":"P Jain","year":"2014","unstructured":"Jain P, Kantarjian H, Ravandi F et al (2014) The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28:973\u2013975. https:\/\/doi.org\/10.1038\/leu.2013.312","journal-title":"Leukemia"},{"key":"4880_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4084\/mjhid.2015.025","volume":"7","author":"MC Tisi","year":"2015","unstructured":"Tisi MC, Ausoni G, Vita MG et al (2015) Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication. Mediterr J Hematol Infect Dis 7:7\u201310. https:\/\/doi.org\/10.4084\/mjhid.2015.025","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"4880_CR25","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372:.https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"4880_CR26","first-page":"2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting - meta-analysis of Observational Studies in Epidemiology (MOOSE) group B. JAMA Neurol 283:2008\u20132012","journal-title":"JAMA Neurol"},{"key":"4880_CR27","unstructured":"NIH. Study Quality assessment tools. National Heart, Lung and Blood Institute. Available at: https:\/\/www.nhlbi.nih.gov\/health-topics\/ study-quality-assessment-tools. Accessed on 19 November 2020."},{"key":"4880_CR28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/bjh.14874","volume":"179","author":"CM Zwaan","year":"2017","unstructured":"Zwaan CM, Kowalczyk J, Schmitt C et al (2017) Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Br J Haematol 179:284\u2013293. https:\/\/doi.org\/10.1111\/bjh.14874","journal-title":"Br J Haematol"},{"key":"4880_CR29","doi-asserted-by":"crossref","unstructured":"Kwok KK, Vincent EC, Gibson JN (2017) Antineoplastic drugs, Seventh Ed. Elsevier","DOI":"10.1016\/B978-0-323-39307-2.00036-9"},{"key":"4880_CR30","first-page":"1135","volume":"3","author":"M Cooper","year":"2008","unstructured":"Cooper M, T, (2008) Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manag 3:1135\u20131141","journal-title":"Ther Clin Risk Manag"},{"key":"4880_CR31","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1200\/JCO.2007.14.1986","volume":"26","author":"V Gandhi","year":"2008","unstructured":"Gandhi V, Tam C, O\u2019Brien S et al (2008) Phase I trial of nelarabine in indolent leukemias. J Clin Oncol 26:1098\u20131105. https:\/\/doi.org\/10.1200\/JCO.2007.14.1986","journal-title":"J Clin Oncol"},{"key":"4880_CR32","doi-asserted-by":"publisher","first-page":"CMT.S1954","DOI":"10.4137\/cmt.s1954","volume":"1","author":"FJ Hernandez-Ilizaliturri","year":"2009","unstructured":"Hernandez-Ilizaliturri FJ, Czuczman MS (2009) A review of nelarabine in the treatment of T-cell lymphoblastic leukemia\/lymphoma. Clin Med Ther 1:CMT.S1954. https:\/\/doi.org\/10.4137\/cmt.s1954","journal-title":"Clin Med Ther"},{"key":"4880_CR33","unstructured":"National Cancer Institute (NCI) (2018) Trial produces practice-changing findings for some children, young adults with leukemia. In: NIH. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2018\/leukemia-nelarabine-improves-survival. Accessed 23 Jul 2021"},{"key":"4880_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4137\/CMO.S4364","volume":"4","author":"AM Roecker","year":"2010","unstructured":"Roecker AM, Stockert A, Kisor DF (2010) Nelarabine in the treatment of refractory T-Cell malignancies. Clin Med Insights Oncol 4:133\u2013141. https:\/\/doi.org\/10.4137\/CMO.S4364","journal-title":"Clin Med Insights Oncol"},{"key":"4880_CR35","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/ajh.21719","volume":"85","author":"C Papayannidis","year":"2010","unstructured":"Papayannidis C, Iacobucci I, Abbenante MC et al (2010) Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. Am J Hematol 85:608. https:\/\/doi.org\/10.1002\/ajh.21719","journal-title":"Am J Hematol"},{"key":"4880_CR36","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","volume":"23","author":"SL Berg","year":"2005","unstructured":"Berg SL, Blaney SM, Devidas M et al (2005) Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the children\u2019s oncology group. J Clin Oncol 23:3376\u20133382. https:\/\/doi.org\/10.1200\/JCO.2005.03.426","journal-title":"J Clin Oncol"},{"key":"4880_CR37","unstructured":"Tapan M. Kadiaan d Varsha Gandhi (2017) Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. In: HHS. https:\/\/pubmed.ncbi.nlm.nih.gov\/27869523\/"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04880-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04880-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04880-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T13:09:18Z","timestamp":1657717758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04880-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4880"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04880-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"24 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors have approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}